What is Immunophotonics?
Headquartered in St. Louis, Missouri, with international operations in Switzerland and China, Immunophotonics is pioneering the field of Interventional Immuno-Oncology. The company's core innovation, the IP-001 platform, is designed to trigger a tumor-specific anticancer immune response, effectively turning localized treatments into systemic therapeutic interventions. This approach addresses significant unmet needs in solid tumor indications, positioning the firm as a high-potential player in the global biotech ecosystem. By integrating advanced photonics with immunological principles, Immunophotonics is carving out a unique niche that bridges the gap between surgical oncology and systemic immunotherapy.
How much funding has Immunophotonics raised?
Immunophotonics has raised a total of $36.3M across 5 funding rounds:
Private Equity
$550K
Private Equity
$2.5M
Series A
$1.8M
Debt
$111K
Series B
$21.4M
Private Equity (2010): $550K, investors not publicly disclosed
Private Equity (2014): $2.5M led by BioGenerator and Cultivation Capital
Series A (2014): $1.8M supported by BioGenerator, Missouri Technology, Cultivation Capital, St Louis Arch Angels, and Billiken Angels Network
Debt (2021): $111K featuring PPP
Series B (2022): $21.4M backed by AC Immune and Zubizoom
Key Investors in Immunophotonics
BioGenerator
A St. Louis-based organization that fosters innovation by providing both venture capital through BioGenerator Ventures and comprehensive operational support via its laboratory facilities.
Cultivation Capital
A venture capital firm specializing in early-to-growth stage investments across life sciences and technology, providing startups with capital and a vast network of strategic partners.
Zubizoom
A family investment platform that manages a diverse portfolio of assets, focusing on high-impact opportunities across multiple global sectors.
What's next for Immunophotonics?
With the recent influx of capital, Immunophotonics is poised to scale its phase 2 development efforts, focusing on the clinical validation of its lead asset across multiple solid tumor types. The strategic roadmap involves deepening its international presence and refining its intellectual property platform to ensure long-term scalability. As the company transitions toward later-stage clinical milestones, the focus will likely shift toward regulatory engagement and potential commercialization partnerships. The sustained interest from institutional investors and strategic partners suggests a clear path toward achieving its mission of transforming cancer care through innovative, systemically active immunotherapy solutions.
See full Immunophotonics company page
